This trial was conducted in a cross-section of UK NHS hospitals and was designed to measure the decision impact of using Oncotype DX test in women with HR+, HER2− breast cancer and 1–3 nodes positive and to measure whether its use increased or decreased the confidence of oncologists and their patients in the final decision on whether chemotherapy should be used. The gene discussed is ERBB2; the disease is breast cancer.